# DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

> **NCT05770037** · PHASE2,PHASE3 · RECRUITING · sponsor: **Cancer Research UK** · enrollment: 30 (estimated)

## Conditions studied

- Haematological Malignancy
- Malignant Neoplasm
- Lymphoproliferative Disorders
- Neoplasms by Histologic Type
- Neoplasms by Site
- Cancer
- Anaplastic Large Cell Lymphoma
- Lymphoma
- Renal Cell Carcinoma
- Neuroblastoma
- Solid Tumour

## Interventions

- **DRUG:** Alectinib

## Key facts

- **NCT ID:** NCT05770037
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-18
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05770037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05770037, "DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05770037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*